Clinical study on Kanglaite Injection combined with bevacizumab in treatment of advanced non-small cell lung cancer
Objective To investigate the efficacy of Kanglaite Injection combined with bevacizumab in treatment of advanced non-small cell lung cancer.Methods Patients(86 cases)with advanced advanced non-small cell lung cancer in Hebei Provincial Hospital of Traditional Chinese Medicine from October 2020 to June 2023 were divided into control(43 cases)and treatment(43 cases)group according to random number table method.Patients in the control group were iv administered with Bevacizumab Injection,the dose was 15 mg/kg after the first chemotherapy,once every 3 weeks,each time at an interval of 3 to 5 days,they were treated for 3 times.Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group,200 mL/time,once daily for 21 d,after 21 d the interval was 3—5 d to enter the next 21 d,they were treated for 3 cycles.After treatment,the clinical evaluations were evaluated,the levels of tumor markers carcinoembryonic antigen,CYFRA21-1 and CA125,the levels of immune function indicators CD8+,CD3+,CD4+and CD4+/CD8+,adverse reactions in two groups before and after treatment were compared.Results After treatment,the disease control rate in the treatment group was 88.37%,which was higher than that in the control group(69.77%,P<0.05).After treatment,the levels of carcinoembryonic antigen,CYFRA21-1,carbohydrate antigen 125,CD3+,CD4+,and CD4+/CD8+ in two groups were significantly decreased,and the level of these indexes in the treatment group was significantly lower than that in the control group(P<0.05).During the treatment,the adverse reaction rate in the treatment group was 51.16%,which was significantly lower than that in the control group(72.09%,P<0.05).Conclusion The combination of Kanglaite Injection and bevacizumab in treatment of advanced non-small cell lung cancer has a high disease control rate,can also improve the level of tumor markers and reduce the adverse reactions of chemotherapy and its adverse effects on immune function.
NETL
NSTL
万方数据
